Dave Murdoch
Director of Corporate Communications
774.405.5719
david.murdoch@us.sumitomo-pharma.com
Thomas Hill
VP, Head of Corporate Communications
and Employee Engagement
949.239.3598
thomas.hill@us.sumitomo-pharma.com
News Releases
Stay up to date with SMPA
The latest company news, press releases, and resources about Sumitomo Pharma America, our employees, our partners, and our latest innovations.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jun 16, 2022
BASEL, Switzerland and NEW YORK, June 17, 2022 (GLOBE NEWSWIRE) — Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced that results of the Phase 3 SPIRIT 1 and SPIRIT 2...
-
Apr 22, 2022
Enzyvant, a commercial-stage biotechnology company with a focus on regenerative medicines for rare diseases, announced today plans to develop a Good Manufacturing Practice (GMP)-compliant...
-
Feb 9, 2022
MARLBOROUGH, Mass. & PRINCETON, N.J., February 09, 2022 08:00 am (BUSINESS WIRE) — Sunovion Pharmaceuticals Inc. (Sunovion) and Otsuka Pharmaceutical Development & Commercialization, Inc....
-
Oct 8, 2021•RETHYMIC is the first and only FDA-approved treatment indicated for immune reconstitution in pediatric patients with congenital athymia
CAMBRIDGE, Mass. & BASEL, Switzerland, October 8, 2021 (GLOBE NEWSWIRE) – Enzyvant today announced the U.S. Food and Drug Administration (FDA) approval of RETHYMIC® (allogeneic processed thymus...
-
Sep 30, 2021-Companies to advance four promising Sunovion compounds for people living with serious neuropsychiatric conditions-
MARLBOROUGH, Mass. & OSAKA, Japan & TOKYO, Japan--(BUSINESS WIRE)-- Sunovion Pharmaceuticals Inc. (Sunovion),its parent company Sumitomo Dainippon Pharma Co., Ltd. (Sumitomo Dainippon Pharma) and...